Molecular targets for therapy in systemic sclerosis
نویسندگان
چکیده
منابع مشابه
Molecular targets for therapy in systemic sclerosis
Despite significant advances have been made in the recent years regarding organ-specific therapies, there is no approved 'disease-modifying' antifibrotic drug for systemic sclerosis (SSc) available to date. Although non-selective immunosuppressive agents are routinely used to treat patients with SSc, large well-controlled studies are lacking for almost all immunosuppressive agents and further e...
متن کاملTherapeutic targets in systemic sclerosis
The precise aetiology of systemic sclerosis (SSc) remains elusive, but significant advances over the past few years have improved our understanding of the underlying pathogenic processes and identified key pathways and mediators that are potential therapeutic targets. The situation is complicated by the clinical heterogeneity of SSc and the differential pathogenesis that underlies the two commo...
متن کاملTargeted Therapy in Systemic Sclerosis
Targeted therapies use an understanding of the pathophysiology of a disease in an individual patient. Although targeted therapy for systemic sclerosis (SSc, scleroderma) has not yet reached the level of patient-specific treatments, recent developments in the understanding of the global pathophysiology of the disease have led to new treatments based on the cells and pathways that have been shown...
متن کامل[Therapy of systemic sclerosis].
The treatment of the patient with systemic sclerosis has greatly improved in the last ten years, because of two kinds of achievements. A number of drugs have been demonstrated to be active in some disease manifestations like alveolitis, pulmonary hypertension and complicated Raynaud's phenomenon. Some of these drugs namely cyclophosphamide and iloprost await to be confirmed as disease modifying...
متن کاملIntracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis.
Tissue fibrosis is a major cause of death in SSc, but therapies that target selectively fibrosis are not yet available for routine clinical use. Recent pre-clinical studies suggest that selective tyrosine kinase inhibitors that target c-Abl, PDGF receptor or Src kinases might be promising targets for anti-fibrotic approaches. Dual inhibition of c-Abl and PDGF receptor by imatinib and nilotinib,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Fibrogenesis & Tissue Repair
سال: 2012
ISSN: 1755-1536
DOI: 10.1186/1755-1536-5-s1-s19